Investing Center Preview – Manage your investments and watch your net worth grow.
LLY:NYSE – Large Cap Stock (Drug Manufacturers)
Eli Lilly and Co – LLY Stock Overview
Last Price | Today's Change | 52-Week Range | Trading Volume |
---|---|---|---|
780.67 | 1.39 (+0.18%) | 677.09 - 972.53 | 1.5 million (Below Avg) |
Market data as of 1:00PM 07/03/25. Quotes are delayed by at least 15 min.
Overview - LLY
Open | 780.46 |
---|---|
Previous Close | 779.28 |
Day's Range | 773.00 - 783.55 |
Market Cap | 739.9B |
Avg Volume (10 Day) | 3.4M |
Price/Earnings (Trailing 12 Mo.) | 63.1x |
Earnings Per Share (Trailing 12 Mo.) | 3.053 |
Dividend Yield | 1.50 (0.77%) |
One-Click Scorecard - LLY


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
Performed well consistently? | Fail |
---|---|
Avoids excess debt? | Fail |
Converting sales to profits? | Fail |
Shareholder's money handled rationally? | Pass |
Increased shareholder value? | Fail |
Consistently increased owner earnings? | Pass |
Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
Pays a cash dividend? | Pass |
---|---|
Room to increase dividends? | Fail |
Increased earnings over time? | Pass |
Borrows within reasonable limits? | Fail |
Stock is undervalued? | Fail |
Have investors caught on? | Fail |
Has support of institutional investors? | Pass |
Has sufficient liquidity? | Pass |
Latest Headlines - LLY
Lilly declares third-quarter 2025 dividend
PR Newswire - Monday 06/23/2025 11:37 AM ET
Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials
PR Newswire - Sunday 06/22/2025 2:31 PM ET
Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine
PR Newswire - Saturday 06/21/2025 9:01 AM ET
Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
PR Newswire - Tuesday 06/17/2025 6:45 AM ET
Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions
PR Newswire - Monday 06/16/2025 6:45 AM ET
Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference
PR Newswire - Monday 06/02/2025 10:00 AM ET
Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting
PR Newswire - Monday 06/02/2025 8:00 AM ET
Industry Position - LLY
LLY | Industry Range | |
---|---|---|
Revenue Growth (1yr) | 32.00% | |
Net Income Growth (1yr) | 102.08% | |
Total Debt/Equity | 2.44 | |
LT Debt/Equity | 2.19 | |
Earnings Yield | 1.58% | |
Price/Sales | 14.30 |
Competitors - LLY
Company | Last | Change |
---|---|---|
1575.00 | +0.90% | |
3296.10 | +0.34% | |
1656.00 | +0.15% | |
Johnson & Johnson | 156.01 | +0.29% |
52.47 | +0.42% |
Data is delayed by at least 15 min.